Top

Osteoporosis International

Published in:

Open Access 01-01-2007 | Original Article

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study

Authors: S. L. Silverman, N. B. Watts, P. D. Delmas, J. L. Lange, R. Lindsay

Published in: Osteoporosis International | Issue 1/2007

Abstract

Introduction

Randomized clinical trials have shown that risedronate and alendronate reduce fractures among women with osteoporosis. The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate.

Methods

Using records of health service utilization from July 2002 through September 2004, we created two cohorts: women (ages 65 and over) receiving risedronate (n = 12,215) or alendronate (n = 21,615). Cox proportional hazard modeling was used to compare the annual incidence of nonvertebral fractures and of hip fractures between cohorts, adjusting for potential differences in risk factors for fractures.

Results

There were 507 nonvertebral fractures and 109 hip fractures. Through one year of therapy, the incidence of nonvertebral fractures in the risedronate cohort (2.0%) was 18% lower (95% CI 2% – 32%) than in the alendronate cohort (2.3%). The incidence of hip fractures in the risedronate cohort (0.4%) was 43% lower (95% CI 13% – 63%) than in the alendronate cohort (0.6%). These results were consistent across a number of sensitivity analyses.

Conclusion

Patients receiving risedronate have lower rates of hip and nonvertebral fractures during their first year of therapy than patients receiving alendronate.

U.S. Department of Health and Human Services (2004) Bone Health and Osteoporosis: A Report of the Surgeon General. U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD

Tosteson A, Solomon D, King AB, Dawson-Hughes B, Burge R, Wong J (2005) Projections of osteoporosis fractures and costs by skeletal sites in the USA. ASBMR 27th annual meeting, Nashville, TN

Melton LJ 3rd, Crowson CS, O'Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9:29–37PubMedCrossRef

U.S. Preventive Services Task Force (2002) Screening for Osteoporosis in Postmenopausal Women: Recommendations and Rationale. Agency for Healthcare Research and Quality, Rockville, MD

Stafford RS, Drieling RL, Hersh AL (2004) National trends in osteoporosis visits and osteoporosis treatment, 1988–2003. Arch Intern Med 164:1525–1530PubMedCrossRef

Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMedCrossRef

Reginster J, Minne HW, Sorensen OH et al (2000). Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91PubMedCrossRef

Liberman UA, Weiss SR, Broll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443PubMedCrossRef

Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541PubMedCrossRef

10.

Cummings SR, Black DM Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMedCrossRef

11.

Chesnut III CH, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRef

12.

Harrington JT, Ste-Marie LG Brandi ML et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129–135PubMedCrossRef

13.

Pols HA, Felsenberg D, Hanley DA et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 9:461–468PubMedCrossRef

14.

Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 85:4118–4124PubMedCrossRef

15.

Nancollas GH, Tang R, Phipps RJ, et al (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627PubMedCrossRef

16.

Rosen CJ, Hochberg MC, Bonnick SL et al; Fosamax Actonel Comparison Trial Investigators (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141–151PubMedCrossRef

17.

Watts NB, Geusens P, Barton IP, Felsenberg D (2005) Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 20:2097–2104PubMedCrossRef

18.

Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586–1592PubMedCrossRef

19.

Klungel OH, Martens EP, Psaty BM et al (1995) Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol 57:1223–1231CrossRef

20.

Psaty BM, Heckbert SR, Koepsell TD et al (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274:620–625PubMedCrossRef

21.

Zhou Z, Rahme E, Abrahamowicz M et al (2005) Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ 172:1187–1194PubMed

22.

Watts NB, Worley K, Solis A, Doyle J, Sheer R (2004) Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm 10:142–151PubMed

23.

Peng RD, Dominici F, Zeger SL (2006) Reproducible epidemiologic research. Am J Epidemiol 163:783–789PubMedCrossRef

24.

Strengthening the reporting of observational studies in epidemiology (STROBE). Available at http://www.strobe-statement.org. Accessed 14 June 2006

25.

Sikka R, Xia F, Aubert RE (2005) Estimating medication persistency using administrative claims data. Am J Manag Care 11:449–457PubMed

26.

Grimes DA, Schulz KF (2002) Bias and causal associations in observational research. Lancet 359:248–252PubMedCrossRef

27.

McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRef

28.

IMS Health, National Prescription Audit Plus, Plymouth Meeting, PA

29.

Ray WA, Griffin MR, Fought RL, Adams ML (1992) Identification of fractures from computerized Medicare files. J Clin Epidemiol 45:703–714PubMedCrossRef

30.

Kelsey JL, Thompson WD, Evans AS (1986) Methods in Observational Epidemiology. Oxford University Press, Oxford

31.

Black N (1996) Why we need observational studies to evaluate the effectiveness of health care. BMJ 312:1215–1218PubMed

32.

Dowd R, Recker RR, Heaney RP (2000) Study subjects and ordinary patients. Osteoporos Int 11:533–536PubMedCrossRef

33.

McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287PubMedCrossRef

34.

McEvoy GK (ed) (2005) AHFS Drug Information 2005. American Society of Health-System Pharmacists, Bethesda, MD

35.

Kane S, Borisov NN, Brixner D (2004) Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate and alendronate: a retrospective cohort study. Am J Manag Care 10:S216–S226

36.

Miller RG, Bolognese M, Worley K, Solis A, Sheer R (2004) Incidence of gastrointestinal events among bisphosphonate subjects in an observational setting. Am J Manag Care 10:S207–S215

Title: Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
Authors: S. L. Silverman
N. B. Watts
P. D. Delmas
J. L. Lange
R. Lindsay
Publication date: 01-01-2007
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 1/2007
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-006-0274-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study

Abstract

Introduction

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2007

Bone mineral density and mandibular bone quality in patients receiving dental implants

Disuse and orchidectomy have additional effects on bone loss in the aged male rat

Severity of vertebral fracture reflects deterioration of bone microarchitecture

Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk – a meta-analysis

Volumetric bone mineral density and bone size in sleep-deprived individuals

The role of osteocytes and bone microstructure in preventing osteoporotic fractures